Re: Economic Evaluation of Everolimus Versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma After Failure of First-Line Sunitinib Editorial Comment

被引：0
|
作者：
Penson, David F.
机构：
来源：
JOURNAL OF UROLOGY | 2012年 / 188卷 / 01期
关键词：
D O I：
10.1016/j.juro.2012.03.096
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：68 / 69
页数：2
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China
    Lin, Jingyang
    Fang, Qingxia
    Zheng, Xiaochun
    PLOS ONE, 2023, 18 (02):
  • [42] Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
    Zhou, Ai-Ping
    Bai, Yuxian
    Song, Yan
    Luo, Hong
    Ren, Xiu-Bao
    Wang, Xiuwen
    Shi, Benkang
    Fu, Cheng
    Cheng, Ying
    Liu, Jiyan
    Qin, Shukui
    Li, Jun
    Li, Hanzhong
    Bai, Xianzhong
    Ye, Dingwei
    Wang, Jinwan
    Ma, Jianhui
    ONCOLOGIST, 2019, 24 (08): : E702 - E708
  • [43] OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON (IFN)-ALFA AS FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC)
    Negrier, S.
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Huang, X.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2008, 19 : 190 - 190
  • [44] A Phase 4 Study of Everolimus to Evaluate Efficacy and Safety in Patients with Metastatic Renal-Cell Carcinoma after Failure of First-Line Sunitinib or Pazopanib (SUNPAZ)
    Schostak, Martin
    de Geeter, Patrick
    Decker, Thomas
    Resch, Anna
    Quiering, Claudia
    Schmitz, Stephan
    UROLOGIA INTERNATIONALIS, 2020, 104 (3-4) : 263 - 268
  • [45] Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
    Zhang, Hai-Liang
    Sheng, Xi-Nan
    Li, Xue-Song
    Wang, Hong-Kai
    Chi, Zhi-Hong
    He, Zhi-Song
    Ye, Ding-Wei
    Guo, Jun
    BMC CANCER, 2017, 17
  • [46] Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
    Hai-Liang Zhang
    Xi-Nan Sheng
    Xue-Song Li
    Hong-Kai Wang
    Zhi-Hong Chi
    Zhi-Song He
    Ding-Wei Ye
    Jun Guo
    BMC Cancer, 17
  • [47] Economic evaluations of sunitinib versus interferon-alfa (IFN-α) in first-line metastatic renal cell carcinoma (mRCC)
    Remak, E.
    Mullins, C. D.
    Akobundu, E.
    Charbonneau, C.
    Woodruff, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience
    Lalani, Aly-Khan A.
    Li, Haocheng
    Heng, Daniel Y. C.
    Wood, Lori
    Kalirai, Austin
    Bjarnason, Georg A.
    Sim, Hao-Wen
    Kollmannsberger, Christian K.
    Kapoor, Anil
    Hotte, Sebastien J.
    Vanhuyse, Marie
    Czaykowski, Piotr
    Reaume, M. Neil
    Soulieres, Denis
    Venner, Peter
    North, Scott
    Basappa, Naveen S.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2017, 11 (3-4): : 112 - 117
  • [49] Re: Randomized Phase II Trial of Sunitinib on an Intermittent versus Continuous Dosing Schedule as First-Line Therapy for Advanced Renal Cell Carcinoma Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2012, 188 (02): : 413 - 414
  • [50] Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma
    Hiles, Jon J.
    Kolesar, Jill M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (02) : 123 - 131
12345